CVS Pharmacy will pay $315 million and implement additional safeguards to resolve federal allegations that its pharmacies improperly filled opioid prescriptions and billed government healthcare programs, while denying wrongdoing.
By yourNEWS Media Newsroom
CVS Pharmacy Inc. and several affiliated companies have agreed to pay $315 million to settle a federal lawsuit accusing the pharmacy chain of unlawfully dispensing addictive opioids and other controlled substances, the Justice Department announced Tuesday, October 13.
The settlement resolves allegations that CVS filled prescriptions without legitimate medical purposes, ignored warning signs of improper prescribing and sought reimbursement from taxpayer-funded healthcare programs for medications that should not have been dispensed.
According to the Justice Department’s announcement, the alleged violations occurred between October 17, 2013, and December 2, 2025, involving potential violations of the Controlled Substances Act and the False Claims Act.
Federal prosecutors alleged that CVS pharmacists dispensed excessive quantities of opioids, filled prescriptions earlier than medically appropriate and supplied dangerous combinations of medications despite warning signs that the prescriptions were illegitimate.
Some prescriptions reportedly originated from known “pill mills,” medical providers accused of issuing large quantities of controlled substances without legitimate medical justification.
The government also alleged that CVS filled so-called “trinity” prescriptions, combinations involving an opioid, a benzodiazepine and a muscle relaxant that can substantially increase the risk of dangerous sedation and overdose.
Investigators said many of the questionable prescriptions were subsequently billed to Medicare and other federal healthcare programs.
Associate Attorney General Stanley Woodward described the settlement as part of the government’s broader effort to address the opioid epidemic.
“Today’s settlement is a significant milestone in the Justice Department’s efforts to combat the opioid epidemic by cracking down on pharmacies who unlawfully fulfill prescriptions for controlled substances,” Woodward said.
The lawsuit, filed in December 2024 during former President Joe Biden’s administration, accused CVS of placing corporate profitability ahead of patient safety.
Prosecutors alleged that staffing shortages, performance targets and employee incentive programs created pressure on pharmacists to process prescriptions quickly without adequately investigating suspicious orders.
The government further claimed that corporate policies prevented pharmacists from sharing certain warnings about potentially problematic prescribers, allowing questionable prescriptions to continue being filled.
CVS has rejected those allegations.
In a statement reported by Reuters, the company said its pharmacists receive extensive training in medication safety and that the settlement does not constitute an admission of wrongdoing.
“Our more than 27,000 CVS pharmacists do their part to help keep America healthy and are highly trained in the safe and appropriate use of all medications,” the company said. “We’re pleased to move forward and put this litigation behind us.”
CVS has previously argued that pharmacy employees were being evaluated against unclear and changing standards governing the dispensing of prescription opioids.
Beyond the financial payment, the settlement requires CVS to strengthen its controlled-substance monitoring procedures through an agreement with the Drug Enforcement Administration.
The company must establish a reporting hotline for employees and the public to identify suspected illegal dispensing, proactively examine prescription patterns across its pharmacies and improve procedures for evaluating healthcare providers suspected of improper prescribing.
Assistant Attorney General Brett Shumate, who leads the Justice Department’s Civil Division, said the new requirements are intended to prevent further violations.
“Today’s settlement requires CVS to implement additional safeguards to ensure that prescriptions for opioids and other controlled substances are dispensed only when medically appropriate,” Shumate said.
The case originated with a whistleblower lawsuit filed by former CVS employee Hillary Estright under the False Claims Act, which permits private individuals to bring certain fraud allegations on behalf of the federal government.
The government subsequently intervened in the case. The whistleblower’s share of the settlement has not yet been determined.
The agreement is the latest in a series of major opioid-related settlements involving pharmaceutical manufacturers, distributors and pharmacy chains.
Over the past decade, companies across the industry have agreed to pay more than $50 billion to resolve government claims connected to the opioid epidemic, with much of the funding designated for addiction treatment, prevention and recovery programs.
Other major pharmacy operators, including Walgreens and Walmart, have reached separate federal settlements involving allegations of improper controlled-substance dispensing.
The opioid crisis has contributed to hundreds of thousands of American deaths over the past two decades, although annual overdose fatalities have declined substantially from their recent peak.
The Justice Department emphasized that the allegations resolved through the CVS settlement remain unproven in court and that no determination of liability has been made.
While CVS denies wrongdoing, the agreement establishes additional federal oversight requirements intended to strengthen prescription monitoring and reduce the risk of medically unnecessary controlled substances reaching patients.
Original article
Comments